High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

MLA

Gao, Hui, et al. “High-Throughput Screening Using Patient-Derived Tumor Xenografts to Predict Clinical Trial Drug Response.” Nature Medicine, vol. 21, no. 11, Nov. 2015, pp. 1318–25. EBSCOhost, https://doi.org/10.1038/nm.3954.

APA

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., Balbin, O. A., Barbe, S., Cai, H., Casey, F., Chatterjee, S., Chiang, D. Y., Chuai, S., Cogan, S. M., Collins, S. D., … Sellers, W. R. (2015). High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine, 21(11), 1318–1325. https://doi.org/10.1038/nm.3954

Chicago

Gao, Hui, Joshua M Korn, Stéphane Ferretti, John E Monahan, Youzhen Wang, Mallika Singh, Chao Zhang, et al. 2015. “High-Throughput Screening Using Patient-Derived Tumor Xenografts to Predict Clinical Trial Drug Response.” Nature Medicine 21 (11): 1318–25. doi:10.1038/nm.3954.